A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay

Background: For screening for monoclonal gammopathies, their prognostic stratification and therapy monitoring, the quantitative determination of free immunoglobulin light chains is a significant component. Nephelometric and turbidimetric test methods have so far been associated with analytical limitations and pitfalls. The new quantitative s-FLC ELISA (Sebia) was tested for its suitability for use in routine clinical diagnostics in an application study in a supraregional laboratory center in Germany.